Itaconate has also been shown to activate the Nrf2 pathway, which reduces the expression of thioredoxin interacting protein in the lung interstitium and mitigates fibroblast–myofibroblast differentiation (FMD)—a key cell phenotype in the development and progression of pulmonary fibrosis. The gene discussed is NFE2L2; the disease is pulmonary fibrosis.